<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/474DBF42-C203-4CBE-96C6-E2BB758BFFD3"><gtr:id>474DBF42-C203-4CBE-96C6-E2BB758BFFD3</gtr:id><gtr:name>Adisseo</gtr:name><gtr:address><gtr:line1>Adisseo</gtr:line1><gtr:line2>Adisseo France SAS</gtr:line2><gtr:line3>42 Avenue Aristide Briand</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/474DBF42-C203-4CBE-96C6-E2BB758BFFD3"><gtr:id>474DBF42-C203-4CBE-96C6-E2BB758BFFD3</gtr:id><gtr:name>Adisseo</gtr:name><gtr:address><gtr:line1>Adisseo</gtr:line1><gtr:line2>Adisseo France SAS</gtr:line2><gtr:line3>42 Avenue Aristide Briand</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C0076838-4929-4F5C-8878-AE6E63D014AA"><gtr:id>C0076838-4929-4F5C-8878-AE6E63D014AA</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:otherNames>Graham</gtr:otherNames><gtr:surname>Berry</gtr:surname><gtr:orcidId>0000-0003-1928-0738</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2E35C80C-27C6-4130-ADB8-4C2D4E37739A"><gtr:id>2E35C80C-27C6-4130-ADB8-4C2D4E37739A</gtr:id><gtr:firstName>Jianliang</gtr:firstName><gtr:surname>Xiao</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/84B0DEBF-D322-4281-815C-68A01818F803"><gtr:id>84B0DEBF-D322-4281-815C-68A01818F803</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Iggo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FG031444%2F1"><gtr:id>F90ED35C-2E80-443A-8722-D70CC0A660DE</gtr:id><gtr:title>Metal-Bronsted Acid Cooperative Catalysis for Asymmetric Direct Reductive Amination</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/G031444/1</gtr:grantReference><gtr:abstractText>Chiral amines are ubiquitous in nature and are the most common functionalities in drug molecules, fine chemicals and new materials. They can be prepared by a number of methods; but the simplest, most efficient and eco-benign preparation is asymmetric direct reductive amination (ADRA) of ketones with hydrogen, which produces chiral amines in one pot. However, this reaction has not found applications in commercial synthesis, because literally no good catalysts are yet available. This proposal attempts to address this Holy Gail problem facing chemical synthesis and asymmetric catalysis by exploiting a novel strategy, Metal-Bronsted Acid Cooperative Catalysis (MBCC). Unlike traditional chemistry developed for ADRA, our approach incorporates three new elements: ionic catalysis, electrophilic activation, and counter anion-directed chiral induction. Under MBCC, an amine condenses with a ketone, forming an imine; this is catalyzed by the Bronsted acid. More importantly, the Bronsted acid then protonates, and thereby activates, the resulting imine by converting it into a highly electrophilic iminium ion. Subsequent hydride transfer, now with a lower barrier, from the metal centre to the iminium carbon atom reduces the C=N double bond. Last not the least, the hydride transfer to which enantiotopic face of the C=N double bond is aided by the conjugate base of the acid through ion-pairing. Clearly, the acid will play a key role in the operation of MBCC, which we believe stands for the most promising approach thus far for developing ADAR. Whilst the concept is designed for ADRA, its potential utility is expected to be much wider. The proposal builds on our recent highly successful studies of asymmetric hydrogenation of imines, key intermediates in ADRA, where unprecedented enantioselectivities have been recorded for a wide range of imines. A key discovery is the use of both hydrogenating metal catalyst and Bronsted acids. Our preliminary results indicate that MBCC drives the reaction and dictates the face selection, pointing to the potential of tackling ADRA via MBCC. However, we have not been able to carry out any mechanistic investigations yet. In order to most efficiently develop catalysts for ADAR by rational design, this project will be built on our preliminary results informed by mechanistic studies. The project will be divided into two synergistic parts, experimental exploration of MBCC for ADRA, and mechanistic and theoretical investigations. We believe experiments alone cannot answer key mechanistic questions, while mechanistic studies can only aid, but not replace, the discovery process</gtr:abstractText><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>453879</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Pfizer on asymmetric transfer hydrogenation</gtr:description><gtr:id>7202205D-2C89-40FB-8A22-11299F1522FC</gtr:id><gtr:impact>A PhD degree was awarded. 
Peer-reviewed publications:
1. Y. Wei, J. Wu, D. Xue, C. Wang, Z. Liu, Z. Zhang, G. Chen, J. Xiao, Synlett 2014, 25, 1295-1298.
2. J. Wu, W. Tang, A. Pettman, J. Xiao, Adv. Synth. Catal. 2013, 355, 35-40.
3. J. Wu, D. Talwar, S. Johnston, M. Yan, J. Xiao, Angew. Chem.-Int. Edit. 2013, 52, 6983-6987.
4. J. Wu, J. H. Barnard, Y. Zhang, D. Talwar, C. M. Robertson, J. Xiao, Chem. Commun. 2013, 49, 7052-
7054.
5. J. Wu, C. Wang, W. Tang, A. Pettman, J. Xiao, Chem.-Eur. J. 2012, 18, 9525-9529.</gtr:impact><gtr:outcomeId>56dd57823d55b7.51598450-1</gtr:outcomeId><gtr:partnerContribution>A PhD studentship.</gtr:partnerContribution><gtr:piContribution>Developed new catalysts for the reduction of N-heterocycles and a new reaction for accessing chiral piperidines.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with AstraZeneca on asymmetric hydrogantion</gtr:description><gtr:id>338AB454-B419-49B9-ACC3-CADADDE7E7C8</gtr:id><gtr:impact>The reseach is ongoing.</gtr:impact><gtr:outcomeId>56d71b901ca085.67527421-1</gtr:outcomeId><gtr:partnerContribution>AZ provided a case award to top-up the studentship.</gtr:partnerContribution><gtr:piContribution>The university provided a PhD studentship.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Adisseo</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Collaboration with Adisseo (France) on transfer hydrogenation</gtr:description><gtr:id>3E7A37F5-8D86-465A-B890-67F5279C2955</gtr:id><gtr:impact>Knowledge transfer to the company.</gtr:impact><gtr:outcomeId>56dd5934815943.29263342-1</gtr:outcomeId><gtr:partnerContribution>Grant to fund a reseacher.</gtr:partnerContribution><gtr:piContribution>Developed conditions for transfer hydrogenation of an Adisseo feedstock.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Both Pfizer and AstraZeneca have provided PhD studentships directly or partially as a result of this research. 
A spin out company, Liverpool ChiroChem, was established partially as a result of this research.</gtr:description><gtr:firstYearOfImpact>2009</gtr:firstYearOfImpact><gtr:id>14E7252D-36B6-4AB9-B8F0-72251134E8CD</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56dd6eefc0cf04.50832224</gtr:outcomeId><gtr:sector>Chemicals</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention relates to an iridium-based catalyst bearing polycyclic rings for hydrogenating reducible moieties, especially imines and iminiums.</gtr:description><gtr:grantRef>EP/G031444/1</gtr:grantRef><gtr:id>A05C2CC7-73BC-470E-9EAA-1E0B655F4F67</gtr:id><gtr:impact>The TSB-EPSRC project EP/K504166 is partly based on this invention, which involves two universities and six companies.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>546396afc72850.92136385</gtr:outcomeId><gtr:patentId>WO2013153407</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>CATALYST COMPOUNDS</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums.</gtr:description><gtr:grantRef>EP/G031444/1</gtr:grantRef><gtr:id>8F23FB2E-A7A2-4B85-BE04-9BB050F96268</gtr:id><gtr:impact>The TSB-EPSRC project EP/K504166 is partly based on this invention, which involves two universities and six companies.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>546395c8eb5ae4.13330272</gtr:outcomeId><gtr:patentId>WO2013153408</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>CATALYST COMPOUNDS</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>The combination of a chiral phosphoric acid with a chiral or an achiral iridium complex affords a catalyst that allows for highly enantioselective hydrogenation of imines and reductive amination. Mechanistic studies suggest that the hydrogenation proceeds through a ternary transition state at the hydride-transfer step, in which the organocatalyst interacts with both the hydride donor and acceptor, effecting highly effective chiral relay.</gtr:description><gtr:exploitationPathways>The concept developed in the research has been and is being exploited by a number of researchers elsewhere.
A spin out company, Liverpool ChiroChem, was established partially as a result of this research.</gtr:exploitationPathways><gtr:id>1F1D1B73-9F2D-4868-A785-1C9D7AD3DC62</gtr:id><gtr:outcomeId>56a5f106035ee8.25407496</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Liverpool ChiroChem</gtr:companyName><gtr:description>The company supplies specialist building blocks and chiral small molecules for pharmaceutical and biotech research/development and draws upon state-of-the-art synthetic methods in asymmetric catalysis developed at the University of Liverpool in collaboration with Pfizer.</gtr:description><gtr:id>87ED6853-7447-47CF-9E46-A525B8BD66E4</gtr:id><gtr:impact>The company has recently won top prize in the 2015 Merseyside Innovation awards
(http://www.merseysideinnovationawards.co.uk/news/liverpool-chirochem-take-the-2015-grand-prize/)
and the Bionow Start Up of the Year Award 2015
(http://www.bionow.co.uk/news/the14thbionowannualawardssuccessfullyshowcas.aspx).</gtr:impact><gtr:outcomeId>54639d8f346f79.74166559</gtr:outcomeId><gtr:url>http://www.liverpoolchirochem.com/</gtr:url><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>EE57899D-00CE-4D75-8DF9-4D76B9A8D81E</gtr:id><gtr:title>Cyclometalated Iridium Complexes as Highly Active Catalysts for the Hydrogenation of Imines</gtr:title><gtr:parentPublicationTitle>Synlett</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03f36af74ec4f9850aa93b5c629d1a42"><gtr:id>03f36af74ec4f9850aa93b5c629d1a42</gtr:id><gtr:otherNames>Xiao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_891444411713770e26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>661037C4-687E-4ABE-B81A-E5752C3D39AD</gtr:id><gtr:title>Cooperative catalysis: combining an achiral metal catalyst with a chiral Br&amp;oslash;nsted acid enables highly enantioselective hydrogenation of imines.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b075caf9f3c926cd0e0e2f0cecad19b"><gtr:id>2b075caf9f3c926cd0e0e2f0cecad19b</gtr:id><gtr:otherNames>Tang W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>doi_53cfc3fc3328b268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B97D8E7-2065-4B49-BB5A-EACCAE1BFAB2</gtr:id><gtr:title>Asymmetric Hydrogenation of Imines via Metal-Organo Cooperative Catalysis</gtr:title><gtr:parentPublicationTitle>Synthesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03f36af74ec4f9850aa93b5c629d1a42"><gtr:id>03f36af74ec4f9850aa93b5c629d1a42</gtr:id><gtr:otherNames>Xiao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>r_578027593463c414b0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF3687D2-3FC7-4ACB-AB0A-D7BD43D15000</gtr:id><gtr:title>pH-Regulated transfer hydrogenation of quinoxalines with a Cp*Ir-diamine catalyst in aqueous media</gtr:title><gtr:parentPublicationTitle>Tetrahedron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976d70ab75b4bb0a47e4714464720429"><gtr:id>976d70ab75b4bb0a47e4714464720429</gtr:id><gtr:otherNames>Tan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_53d00c00cf3ca28f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60B812CA-BE92-48A0-8D90-0489386024A2</gtr:id><gtr:title>Cooperative catalysis through noncovalent interactions.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b075caf9f3c926cd0e0e2f0cecad19b"><gtr:id>2b075caf9f3c926cd0e0e2f0cecad19b</gtr:id><gtr:otherNames>Tang W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>doi_53cfc1fc19b3153d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9865A7B4-11A0-47F3-9A11-59E1803FA3F5</gtr:id><gtr:title>The remarkable effect of a simple ion: iodide-promoted transfer hydrogenation of heteroaromatics.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eae989d7fe2595c2c6dea57f94ec9e5"><gtr:id>3eae989d7fe2595c2c6dea57f94ec9e5</gtr:id><gtr:otherNames>Wu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>doi_53cfc3fc31b74b1c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4998330F-0F28-4BBD-A5F4-2431AB000C55</gtr:id><gtr:title>Acceptorless dehydrogenation of nitrogen heterocycles with a versatile iridium catalyst.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eae989d7fe2595c2c6dea57f94ec9e5"><gtr:id>3eae989d7fe2595c2c6dea57f94ec9e5</gtr:id><gtr:otherNames>Wu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>doi_53cfc1fc19f4c9b3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D08F9F2B-5B6D-4C05-AF74-0A35CC767157</gtr:id><gtr:title>Efficient and Chemoselective Reduction of Pyridines to Tetrahydropyridines and Piperidines
 
 Rhodium-Catalyzed Transfer Hydrogenation</gtr:title><gtr:parentPublicationTitle>Advanced Synthesis &amp; Catalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eae989d7fe2595c2c6dea57f94ec9e5"><gtr:id>3eae989d7fe2595c2c6dea57f94ec9e5</gtr:id><gtr:otherNames>Wu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_53cfc0fc042c3db1</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/G031444/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>64596636-AE88-4F6E-A816-9C4C203E1197</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Catalysis &amp; surfaces</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>60</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>41B6965D-D659-4099-9434-7C61B7E5BEF2</gtr:id><gtr:percentage>30</gtr:percentage><gtr:text>Asymmetric Chemistry</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>35E9CECD-F211-4914-9F91-4B8FB76B773D</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Catalysis &amp; Applied Catalysis</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>454398F2-57A6-4959-8845-0F248CF4D5C4</gtr:id><gtr:percentage>30</gtr:percentage><gtr:text>Chemical Synthetic Methodology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>